nodes	percent_of_prediction	percent_of_DWPC	metapath
Felbamate—CYP3A4—bone cancer	0.749	1	CbGaD
Felbamate—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00259	0.138	CbGpPWpGaD
Felbamate—GRIN2A—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00146	0.0782	CbGpPWpGaD
Felbamate—GRIN2B—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00124	0.0665	CbGpPWpGaD
Felbamate—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000849	0.0453	CbGpPWpGaD
Felbamate—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000655	0.035	CbGpPWpGaD
Felbamate—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.000508	0.0271	CbGpPWpGaD
Felbamate—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00049	0.0262	CbGpPWpGaD
Felbamate—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000459	0.0245	CbGpPWpGaD
Felbamate—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.000432	0.023	CbGpPWpGaD
Felbamate—GRIN2A—Post NMDA receptor activation events—BRAF—bone cancer	0.000418	0.0223	CbGpPWpGaD
Felbamate—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.00041	0.0219	CbGpPWpGaD
Felbamate—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000394	0.021	CbGpPWpGaD
Felbamate—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000394	0.021	CbGpPWpGaD
Felbamate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.000385	0.0205	CbGpPWpGaD
Felbamate—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000371	0.0198	CbGpPWpGaD
Felbamate—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000365	0.0195	CbGpPWpGaD
Felbamate—GRIN2B—Post NMDA receptor activation events—BRAF—bone cancer	0.000355	0.019	CbGpPWpGaD
Felbamate—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000351	0.00151	CcSEcCtD
Felbamate—Cardiac arrest—Doxorubicin—bone cancer	0.00035	0.00151	CcSEcCtD
Felbamate—Pancytopenia—Methotrexate—bone cancer	0.000349	0.0015	CcSEcCtD
Felbamate—Mood swings—Doxorubicin—bone cancer	0.000349	0.0015	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000347	0.00149	CcSEcCtD
Felbamate—Ataxia—Doxorubicin—bone cancer	0.000346	0.00149	CcSEcCtD
Felbamate—Dysphagia—Epirubicin—bone cancer	0.000344	0.00148	CcSEcCtD
Felbamate—Asthma—Epirubicin—bone cancer	0.000344	0.00148	CcSEcCtD
Felbamate—Dysuria—Methotrexate—bone cancer	0.000344	0.00148	CcSEcCtD
Felbamate—Dehydration—Doxorubicin—bone cancer	0.000342	0.00147	CcSEcCtD
Felbamate—Paraesthesia—Cisplatin—bone cancer	0.000342	0.00147	CcSEcCtD
Felbamate—Upper respiratory tract infection—Methotrexate—bone cancer	0.000341	0.00147	CcSEcCtD
Felbamate—Eosinophilia—Epirubicin—bone cancer	0.00034	0.00147	CcSEcCtD
Felbamate—Dyspnoea—Cisplatin—bone cancer	0.000339	0.00146	CcSEcCtD
Felbamate—Pancreatitis—Epirubicin—bone cancer	0.000337	0.00145	CcSEcCtD
Felbamate—Photosensitivity reaction—Methotrexate—bone cancer	0.000335	0.00144	CcSEcCtD
Felbamate—Hypokalaemia—Doxorubicin—bone cancer	0.000335	0.00144	CcSEcCtD
Felbamate—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000331	0.00143	CcSEcCtD
Felbamate—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000331	0.00143	CcSEcCtD
Felbamate—Decreased appetite—Cisplatin—bone cancer	0.000331	0.00142	CcSEcCtD
Felbamate—Pneumonia—Methotrexate—bone cancer	0.000329	0.00142	CcSEcCtD
Felbamate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.000327	0.0175	CbGpPWpGaD
Felbamate—Depression—Methotrexate—bone cancer	0.000327	0.00141	CcSEcCtD
Felbamate—Pancytopenia—Epirubicin—bone cancer	0.000326	0.00141	CcSEcCtD
Felbamate—Gastritis—Doxorubicin—bone cancer	0.000326	0.0014	CcSEcCtD
Felbamate—Pain—Cisplatin—bone cancer	0.000326	0.0014	CcSEcCtD
Felbamate—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000325	0.0014	CcSEcCtD
Felbamate—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000325	0.0014	CcSEcCtD
Felbamate—Muscular weakness—Doxorubicin—bone cancer	0.000325	0.0014	CcSEcCtD
Felbamate—Dysuria—Epirubicin—bone cancer	0.000321	0.00138	CcSEcCtD
Felbamate—Upper respiratory tract infection—Epirubicin—bone cancer	0.00032	0.00138	CcSEcCtD
Felbamate—Conjunctivitis—Methotrexate—bone cancer	0.000318	0.00137	CcSEcCtD
Felbamate—Dysphagia—Doxorubicin—bone cancer	0.000318	0.00137	CcSEcCtD
Felbamate—Asthma—Doxorubicin—bone cancer	0.000318	0.00137	CcSEcCtD
Felbamate—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000316	0.0169	CbGpPWpGaD
Felbamate—Eosinophilia—Doxorubicin—bone cancer	0.000315	0.00136	CcSEcCtD
Felbamate—Sweating—Methotrexate—bone cancer	0.000314	0.00135	CcSEcCtD
Felbamate—Photosensitivity reaction—Epirubicin—bone cancer	0.000314	0.00135	CcSEcCtD
Felbamate—Feeling abnormal—Cisplatin—bone cancer	0.000314	0.00135	CcSEcCtD
Felbamate—Weight increased—Epirubicin—bone cancer	0.000313	0.00135	CcSEcCtD
Felbamate—Haematuria—Methotrexate—bone cancer	0.000312	0.00134	CcSEcCtD
Felbamate—Pancreatitis—Doxorubicin—bone cancer	0.000312	0.00134	CcSEcCtD
Felbamate—GRIN2B—ErbB4 signaling events—MDM2—bone cancer	0.000311	0.0166	CbGpPWpGaD
Felbamate—Weight decreased—Epirubicin—bone cancer	0.000311	0.00134	CcSEcCtD
Felbamate—Hyperglycaemia—Epirubicin—bone cancer	0.00031	0.00134	CcSEcCtD
Felbamate—Epistaxis—Methotrexate—bone cancer	0.000309	0.00133	CcSEcCtD
Felbamate—Pneumonia—Epirubicin—bone cancer	0.000308	0.00133	CcSEcCtD
Felbamate—Agranulocytosis—Methotrexate—bone cancer	0.000306	0.00132	CcSEcCtD
Felbamate—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000304	0.0162	CbGpPWpGaD
Felbamate—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000304	0.00131	CcSEcCtD
Felbamate—Pancytopenia—Doxorubicin—bone cancer	0.000302	0.0013	CcSEcCtD
Felbamate—Body temperature increased—Cisplatin—bone cancer	0.000301	0.0013	CcSEcCtD
Felbamate—Jaundice—Epirubicin—bone cancer	0.000299	0.00129	CcSEcCtD
Felbamate—Conjunctivitis—Epirubicin—bone cancer	0.000298	0.00128	CcSEcCtD
Felbamate—Urinary tract infection—Epirubicin—bone cancer	0.000298	0.00128	CcSEcCtD
Felbamate—Dysuria—Doxorubicin—bone cancer	0.000297	0.00128	CcSEcCtD
Felbamate—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000296	0.00127	CcSEcCtD
Felbamate—Haemoglobin—Methotrexate—bone cancer	0.000296	0.00127	CcSEcCtD
Felbamate—Haemorrhage—Methotrexate—bone cancer	0.000294	0.00127	CcSEcCtD
Felbamate—Hepatitis—Methotrexate—bone cancer	0.000294	0.00127	CcSEcCtD
Felbamate—Sweating—Epirubicin—bone cancer	0.000294	0.00127	CcSEcCtD
Felbamate—Haematuria—Epirubicin—bone cancer	0.000292	0.00126	CcSEcCtD
Felbamate—Pharyngitis—Methotrexate—bone cancer	0.000292	0.00126	CcSEcCtD
Felbamate—Photosensitivity reaction—Doxorubicin—bone cancer	0.00029	0.00125	CcSEcCtD
Felbamate—Weight increased—Doxorubicin—bone cancer	0.000289	0.00125	CcSEcCtD
Felbamate—Epistaxis—Epirubicin—bone cancer	0.000289	0.00124	CcSEcCtD
Felbamate—Weight decreased—Doxorubicin—bone cancer	0.000288	0.00124	CcSEcCtD
Felbamate—Sinusitis—Epirubicin—bone cancer	0.000288	0.00124	CcSEcCtD
Felbamate—Hyperglycaemia—Doxorubicin—bone cancer	0.000287	0.00124	CcSEcCtD
Felbamate—Agranulocytosis—Epirubicin—bone cancer	0.000286	0.00123	CcSEcCtD
Felbamate—Pneumonia—Doxorubicin—bone cancer	0.000285	0.00123	CcSEcCtD
Felbamate—Visual impairment—Methotrexate—bone cancer	0.000283	0.00122	CcSEcCtD
Felbamate—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000282	0.0151	CbGpPWpGaD
Felbamate—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000281	0.00121	CcSEcCtD
Felbamate—Bradycardia—Epirubicin—bone cancer	0.00028	0.00121	CcSEcCtD
Felbamate—Erythema multiforme—Methotrexate—bone cancer	0.000278	0.0012	CcSEcCtD
Felbamate—Haemoglobin—Epirubicin—bone cancer	0.000277	0.00119	CcSEcCtD
Felbamate—Jaundice—Doxorubicin—bone cancer	0.000276	0.00119	CcSEcCtD
Felbamate—GRIN2B—BDNF signaling pathway—EIF2S1—bone cancer	0.000276	0.0147	CbGpPWpGaD
Felbamate—Rhinitis—Epirubicin—bone cancer	0.000276	0.00119	CcSEcCtD
Felbamate—Urinary tract infection—Doxorubicin—bone cancer	0.000276	0.00119	CcSEcCtD
Felbamate—Conjunctivitis—Doxorubicin—bone cancer	0.000276	0.00119	CcSEcCtD
Felbamate—Haemorrhage—Epirubicin—bone cancer	0.000275	0.00118	CcSEcCtD
Felbamate—Hepatitis—Epirubicin—bone cancer	0.000275	0.00118	CcSEcCtD
Felbamate—Asthenia—Cisplatin—bone cancer	0.000273	0.00118	CcSEcCtD
Felbamate—Pharyngitis—Epirubicin—bone cancer	0.000273	0.00118	CcSEcCtD
Felbamate—Sweating—Doxorubicin—bone cancer	0.000272	0.00117	CcSEcCtD
Felbamate—Haematuria—Doxorubicin—bone cancer	0.00027	0.00116	CcSEcCtD
Felbamate—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000268	0.0143	CbGpPWpGaD
Felbamate—Epistaxis—Doxorubicin—bone cancer	0.000268	0.00115	CcSEcCtD
Felbamate—Sinusitis—Doxorubicin—bone cancer	0.000266	0.00115	CcSEcCtD
Felbamate—Visual impairment—Epirubicin—bone cancer	0.000265	0.00114	CcSEcCtD
Felbamate—Agranulocytosis—Doxorubicin—bone cancer	0.000265	0.00114	CcSEcCtD
Felbamate—Chills—Methotrexate—bone cancer	0.000264	0.00114	CcSEcCtD
Felbamate—Diarrhoea—Cisplatin—bone cancer	0.00026	0.00112	CcSEcCtD
Felbamate—Erythema multiforme—Epirubicin—bone cancer	0.00026	0.00112	CcSEcCtD
Felbamate—Alopecia—Methotrexate—bone cancer	0.00026	0.00112	CcSEcCtD
Felbamate—Bradycardia—Doxorubicin—bone cancer	0.000259	0.00112	CcSEcCtD
Felbamate—Haemoglobin—Doxorubicin—bone cancer	0.000256	0.0011	CcSEcCtD
Felbamate—Flushing—Epirubicin—bone cancer	0.000255	0.0011	CcSEcCtD
Felbamate—Rhinitis—Doxorubicin—bone cancer	0.000255	0.0011	CcSEcCtD
Felbamate—Haemorrhage—Doxorubicin—bone cancer	0.000255	0.0011	CcSEcCtD
Felbamate—Hepatitis—Doxorubicin—bone cancer	0.000255	0.0011	CcSEcCtD
Felbamate—Pharyngitis—Doxorubicin—bone cancer	0.000253	0.00109	CcSEcCtD
Felbamate—Dysgeusia—Methotrexate—bone cancer	0.000251	0.00108	CcSEcCtD
Felbamate—Chills—Epirubicin—bone cancer	0.000247	0.00106	CcSEcCtD
Felbamate—Visual impairment—Doxorubicin—bone cancer	0.000245	0.00106	CcSEcCtD
Felbamate—Alopecia—Epirubicin—bone cancer	0.000243	0.00105	CcSEcCtD
Felbamate—Vomiting—Cisplatin—bone cancer	0.000242	0.00104	CcSEcCtD
Felbamate—Erythema multiforme—Doxorubicin—bone cancer	0.000241	0.00104	CcSEcCtD
Felbamate—Rash—Cisplatin—bone cancer	0.00024	0.00103	CcSEcCtD
Felbamate—Dermatitis—Cisplatin—bone cancer	0.00024	0.00103	CcSEcCtD
Felbamate—Ill-defined disorder—Methotrexate—bone cancer	0.000237	0.00102	CcSEcCtD
Felbamate—Anaemia—Methotrexate—bone cancer	0.000237	0.00102	CcSEcCtD
Felbamate—Flushing—Doxorubicin—bone cancer	0.000236	0.00102	CcSEcCtD
Felbamate—Flatulence—Epirubicin—bone cancer	0.000236	0.00102	CcSEcCtD
Felbamate—Tension—Epirubicin—bone cancer	0.000235	0.00101	CcSEcCtD
Felbamate—Dysgeusia—Epirubicin—bone cancer	0.000235	0.00101	CcSEcCtD
Felbamate—Nervousness—Epirubicin—bone cancer	0.000233	0.001	CcSEcCtD
Felbamate—Malaise—Methotrexate—bone cancer	0.000231	0.000994	CcSEcCtD
Felbamate—Leukopenia—Methotrexate—bone cancer	0.000229	0.000987	CcSEcCtD
Felbamate—Chills—Doxorubicin—bone cancer	0.000228	0.000984	CcSEcCtD
Felbamate—Nausea—Cisplatin—bone cancer	0.000226	0.000974	CcSEcCtD
Felbamate—Alopecia—Doxorubicin—bone cancer	0.000225	0.000969	CcSEcCtD
Felbamate—Cough—Methotrexate—bone cancer	0.000223	0.000962	CcSEcCtD
Felbamate—Ill-defined disorder—Epirubicin—bone cancer	0.000222	0.000957	CcSEcCtD
Felbamate—Anaemia—Epirubicin—bone cancer	0.000221	0.000953	CcSEcCtD
Felbamate—Agitation—Epirubicin—bone cancer	0.00022	0.000948	CcSEcCtD
Felbamate—Flatulence—Doxorubicin—bone cancer	0.000218	0.00094	CcSEcCtD
Felbamate—Arthralgia—Methotrexate—bone cancer	0.000218	0.000938	CcSEcCtD
Felbamate—Chest pain—Methotrexate—bone cancer	0.000218	0.000938	CcSEcCtD
Felbamate—Myalgia—Methotrexate—bone cancer	0.000218	0.000938	CcSEcCtD
Felbamate—Tension—Doxorubicin—bone cancer	0.000217	0.000937	CcSEcCtD
Felbamate—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000217	0.0116	CbGpPWpGaD
Felbamate—Dysgeusia—Doxorubicin—bone cancer	0.000217	0.000935	CcSEcCtD
Felbamate—Malaise—Epirubicin—bone cancer	0.000216	0.00093	CcSEcCtD
Felbamate—Discomfort—Methotrexate—bone cancer	0.000215	0.000927	CcSEcCtD
Felbamate—Nervousness—Doxorubicin—bone cancer	0.000215	0.000927	CcSEcCtD
Felbamate—Leukopenia—Epirubicin—bone cancer	0.000214	0.000923	CcSEcCtD
Felbamate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000213	0.0114	CbGpPWpGaD
Felbamate—Palpitations—Epirubicin—bone cancer	0.000212	0.000912	CcSEcCtD
Felbamate—Confusional state—Methotrexate—bone cancer	0.000211	0.000907	CcSEcCtD
Felbamate—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.00021	0.0112	CbGpPWpGaD
Felbamate—Cough—Epirubicin—bone cancer	0.000209	0.0009	CcSEcCtD
Felbamate—Anaphylactic shock—Methotrexate—bone cancer	0.000209	0.0009	CcSEcCtD
Felbamate—Infection—Methotrexate—bone cancer	0.000208	0.000894	CcSEcCtD
Felbamate—Hypertension—Epirubicin—bone cancer	0.000207	0.000891	CcSEcCtD
Felbamate—Ill-defined disorder—Doxorubicin—bone cancer	0.000206	0.000886	CcSEcCtD
Felbamate—Anaemia—Doxorubicin—bone cancer	0.000205	0.000882	CcSEcCtD
Felbamate—Thrombocytopenia—Methotrexate—bone cancer	0.000205	0.000881	CcSEcCtD
Felbamate—Myalgia—Epirubicin—bone cancer	0.000204	0.000878	CcSEcCtD
Felbamate—Arthralgia—Epirubicin—bone cancer	0.000204	0.000878	CcSEcCtD
Felbamate—Chest pain—Epirubicin—bone cancer	0.000204	0.000878	CcSEcCtD
Felbamate—Agitation—Doxorubicin—bone cancer	0.000204	0.000877	CcSEcCtD
Felbamate—Anxiety—Epirubicin—bone cancer	0.000203	0.000875	CcSEcCtD
Felbamate—Hyperhidrosis—Methotrexate—bone cancer	0.000202	0.00087	CcSEcCtD
Felbamate—Discomfort—Epirubicin—bone cancer	0.000201	0.000868	CcSEcCtD
Felbamate—Malaise—Doxorubicin—bone cancer	0.0002	0.000861	CcSEcCtD
Felbamate—Dry mouth—Epirubicin—bone cancer	0.000199	0.000859	CcSEcCtD
Felbamate—Anorexia—Methotrexate—bone cancer	0.000199	0.000857	CcSEcCtD
Felbamate—Leukopenia—Doxorubicin—bone cancer	0.000198	0.000854	CcSEcCtD
Felbamate—Confusional state—Epirubicin—bone cancer	0.000197	0.000849	CcSEcCtD
Felbamate—Palpitations—Doxorubicin—bone cancer	0.000196	0.000843	CcSEcCtD
Felbamate—Anaphylactic shock—Epirubicin—bone cancer	0.000195	0.000842	CcSEcCtD
Felbamate—Oedema—Epirubicin—bone cancer	0.000195	0.000842	CcSEcCtD
Felbamate—Hypotension—Methotrexate—bone cancer	0.000195	0.000841	CcSEcCtD
Felbamate—Infection—Epirubicin—bone cancer	0.000194	0.000836	CcSEcCtD
Felbamate—Cough—Doxorubicin—bone cancer	0.000193	0.000833	CcSEcCtD
Felbamate—Thrombocytopenia—Epirubicin—bone cancer	0.000191	0.000824	CcSEcCtD
Felbamate—Hypertension—Doxorubicin—bone cancer	0.000191	0.000824	CcSEcCtD
Felbamate—Tachycardia—Epirubicin—bone cancer	0.000191	0.000822	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00019	0.00082	CcSEcCtD
Felbamate—Hyperhidrosis—Epirubicin—bone cancer	0.000189	0.000814	CcSEcCtD
Felbamate—Insomnia—Methotrexate—bone cancer	0.000189	0.000814	CcSEcCtD
Felbamate—Myalgia—Doxorubicin—bone cancer	0.000189	0.000813	CcSEcCtD
Felbamate—Arthralgia—Doxorubicin—bone cancer	0.000189	0.000813	CcSEcCtD
Felbamate—Chest pain—Doxorubicin—bone cancer	0.000189	0.000813	CcSEcCtD
Felbamate—Anxiety—Doxorubicin—bone cancer	0.000188	0.00081	CcSEcCtD
Felbamate—Paraesthesia—Methotrexate—bone cancer	0.000188	0.000808	CcSEcCtD
Felbamate—Discomfort—Doxorubicin—bone cancer	0.000186	0.000803	CcSEcCtD
Felbamate—Anorexia—Epirubicin—bone cancer	0.000186	0.000802	CcSEcCtD
Felbamate—Dyspnoea—Methotrexate—bone cancer	0.000186	0.000802	CcSEcCtD
Felbamate—Somnolence—Methotrexate—bone cancer	0.000186	0.0008	CcSEcCtD
Felbamate—Dry mouth—Doxorubicin—bone cancer	0.000185	0.000795	CcSEcCtD
Felbamate—Dyspepsia—Methotrexate—bone cancer	0.000184	0.000792	CcSEcCtD
Felbamate—Hypotension—Epirubicin—bone cancer	0.000183	0.000787	CcSEcCtD
Felbamate—Confusional state—Doxorubicin—bone cancer	0.000182	0.000785	CcSEcCtD
Felbamate—Decreased appetite—Methotrexate—bone cancer	0.000182	0.000782	CcSEcCtD
Felbamate—Anaphylactic shock—Doxorubicin—bone cancer	0.000181	0.000779	CcSEcCtD
Felbamate—Oedema—Doxorubicin—bone cancer	0.000181	0.000779	CcSEcCtD
Felbamate—Fatigue—Methotrexate—bone cancer	0.00018	0.000776	CcSEcCtD
Felbamate—Infection—Doxorubicin—bone cancer	0.00018	0.000774	CcSEcCtD
Felbamate—Pain—Methotrexate—bone cancer	0.000179	0.000769	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000178	0.000767	CcSEcCtD
Felbamate—Thrombocytopenia—Doxorubicin—bone cancer	0.000177	0.000763	CcSEcCtD
Felbamate—Insomnia—Epirubicin—bone cancer	0.000177	0.000761	CcSEcCtD
Felbamate—Tachycardia—Doxorubicin—bone cancer	0.000177	0.00076	CcSEcCtD
Felbamate—Paraesthesia—Epirubicin—bone cancer	0.000176	0.000756	CcSEcCtD
Felbamate—Hyperhidrosis—Doxorubicin—bone cancer	0.000175	0.000753	CcSEcCtD
Felbamate—Dyspnoea—Epirubicin—bone cancer	0.000174	0.000751	CcSEcCtD
Felbamate—Somnolence—Epirubicin—bone cancer	0.000174	0.000748	CcSEcCtD
Felbamate—Anorexia—Doxorubicin—bone cancer	0.000172	0.000742	CcSEcCtD
Felbamate—Feeling abnormal—Methotrexate—bone cancer	0.000172	0.000741	CcSEcCtD
Felbamate—Dyspepsia—Epirubicin—bone cancer	0.000172	0.000741	CcSEcCtD
Felbamate—Gastrointestinal pain—Methotrexate—bone cancer	0.000171	0.000736	CcSEcCtD
Felbamate—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00017	0.00909	CbGpPWpGaD
Felbamate—Decreased appetite—Epirubicin—bone cancer	0.00017	0.000732	CcSEcCtD
Felbamate—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00017	0.00905	CbGpPWpGaD
Felbamate—Hypotension—Doxorubicin—bone cancer	0.000169	0.000728	CcSEcCtD
Felbamate—Fatigue—Epirubicin—bone cancer	0.000169	0.000726	CcSEcCtD
Felbamate—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000168	0.00897	CbGpPWpGaD
Felbamate—Pain—Epirubicin—bone cancer	0.000167	0.00072	CcSEcCtD
Felbamate—Constipation—Epirubicin—bone cancer	0.000167	0.00072	CcSEcCtD
Felbamate—Urticaria—Methotrexate—bone cancer	0.000166	0.000715	CcSEcCtD
Felbamate—Abdominal pain—Methotrexate—bone cancer	0.000165	0.000711	CcSEcCtD
Felbamate—Body temperature increased—Methotrexate—bone cancer	0.000165	0.000711	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000165	0.00071	CcSEcCtD
Felbamate—Insomnia—Doxorubicin—bone cancer	0.000164	0.000704	CcSEcCtD
Felbamate—Paraesthesia—Doxorubicin—bone cancer	0.000162	0.000699	CcSEcCtD
Felbamate—Dyspnoea—Doxorubicin—bone cancer	0.000161	0.000694	CcSEcCtD
Felbamate—Feeling abnormal—Epirubicin—bone cancer	0.000161	0.000694	CcSEcCtD
Felbamate—Somnolence—Doxorubicin—bone cancer	0.000161	0.000692	CcSEcCtD
Felbamate—Gastrointestinal pain—Epirubicin—bone cancer	0.00016	0.000688	CcSEcCtD
Felbamate—Dyspepsia—Doxorubicin—bone cancer	0.000159	0.000686	CcSEcCtD
Felbamate—GRIN2B—EPH-Ephrin signaling—MMP2—bone cancer	0.000159	0.00848	CbGpPWpGaD
Felbamate—Decreased appetite—Doxorubicin—bone cancer	0.000157	0.000677	CcSEcCtD
Felbamate—Fatigue—Doxorubicin—bone cancer	0.000156	0.000672	CcSEcCtD
Felbamate—Urticaria—Epirubicin—bone cancer	0.000155	0.000669	CcSEcCtD
Felbamate—Pain—Doxorubicin—bone cancer	0.000155	0.000666	CcSEcCtD
Felbamate—Constipation—Doxorubicin—bone cancer	0.000155	0.000666	CcSEcCtD
Felbamate—Abdominal pain—Epirubicin—bone cancer	0.000155	0.000665	CcSEcCtD
Felbamate—Body temperature increased—Epirubicin—bone cancer	0.000155	0.000665	CcSEcCtD
Felbamate—Asthenia—Methotrexate—bone cancer	0.00015	0.000645	CcSEcCtD
Felbamate—Feeling abnormal—Doxorubicin—bone cancer	0.000149	0.000642	CcSEcCtD
Felbamate—Gastrointestinal pain—Doxorubicin—bone cancer	0.000148	0.000637	CcSEcCtD
Felbamate—Pruritus—Methotrexate—bone cancer	0.000148	0.000636	CcSEcCtD
Felbamate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000144	0.00769	CbGpPWpGaD
Felbamate—Urticaria—Doxorubicin—bone cancer	0.000144	0.000619	CcSEcCtD
Felbamate—Body temperature increased—Doxorubicin—bone cancer	0.000143	0.000616	CcSEcCtD
Felbamate—Abdominal pain—Doxorubicin—bone cancer	0.000143	0.000616	CcSEcCtD
Felbamate—Diarrhoea—Methotrexate—bone cancer	0.000143	0.000615	CcSEcCtD
Felbamate—Asthenia—Epirubicin—bone cancer	0.00014	0.000604	CcSEcCtD
Felbamate—Pruritus—Epirubicin—bone cancer	0.000138	0.000596	CcSEcCtD
Felbamate—Dizziness—Methotrexate—bone cancer	0.000138	0.000595	CcSEcCtD
Felbamate—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000138	0.00737	CbGpPWpGaD
Felbamate—Diarrhoea—Epirubicin—bone cancer	0.000134	0.000576	CcSEcCtD
Felbamate—Vomiting—Methotrexate—bone cancer	0.000133	0.000572	CcSEcCtD
Felbamate—Rash—Methotrexate—bone cancer	0.000132	0.000567	CcSEcCtD
Felbamate—Dermatitis—Methotrexate—bone cancer	0.000132	0.000567	CcSEcCtD
Felbamate—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000131	0.00701	CbGpPWpGaD
Felbamate—Headache—Methotrexate—bone cancer	0.000131	0.000564	CcSEcCtD
Felbamate—Asthenia—Doxorubicin—bone cancer	0.00013	0.000559	CcSEcCtD
Felbamate—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00013	0.00692	CbGpPWpGaD
Felbamate—Dizziness—Epirubicin—bone cancer	0.000129	0.000557	CcSEcCtD
Felbamate—Pruritus—Doxorubicin—bone cancer	0.000128	0.000551	CcSEcCtD
Felbamate—Vomiting—Epirubicin—bone cancer	0.000124	0.000535	CcSEcCtD
Felbamate—Nausea—Methotrexate—bone cancer	0.000124	0.000534	CcSEcCtD
Felbamate—Diarrhoea—Doxorubicin—bone cancer	0.000124	0.000533	CcSEcCtD
Felbamate—Rash—Epirubicin—bone cancer	0.000123	0.000531	CcSEcCtD
Felbamate—Dermatitis—Epirubicin—bone cancer	0.000123	0.00053	CcSEcCtD
Felbamate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000123	0.00654	CbGpPWpGaD
Felbamate—Headache—Epirubicin—bone cancer	0.000122	0.000527	CcSEcCtD
Felbamate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000121	0.00645	CbGpPWpGaD
Felbamate—Dizziness—Doxorubicin—bone cancer	0.00012	0.000515	CcSEcCtD
Felbamate—GRIN2B—EPH-Ephrin signaling—MMP9—bone cancer	0.000119	0.00637	CbGpPWpGaD
Felbamate—Nausea—Epirubicin—bone cancer	0.000116	0.0005	CcSEcCtD
Felbamate—Vomiting—Doxorubicin—bone cancer	0.000115	0.000495	CcSEcCtD
Felbamate—Rash—Doxorubicin—bone cancer	0.000114	0.000491	CcSEcCtD
Felbamate—Dermatitis—Doxorubicin—bone cancer	0.000114	0.000491	CcSEcCtD
Felbamate—Headache—Doxorubicin—bone cancer	0.000113	0.000488	CcSEcCtD
Felbamate—GRIN2A—Alzheimers Disease—TP53—bone cancer	0.000109	0.00585	CbGpPWpGaD
Felbamate—GRIN2A—Transmission across Chemical Synapses—BRAF—bone cancer	0.000108	0.00578	CbGpPWpGaD
Felbamate—Nausea—Doxorubicin—bone cancer	0.000107	0.000463	CcSEcCtD
Felbamate—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000106	0.00568	CbGpPWpGaD
Felbamate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000103	0.00548	CbGpPWpGaD
Felbamate—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	9.67e-05	0.00517	CbGpPWpGaD
Felbamate—GRIN2B—Alzheimers Disease—TP53—bone cancer	9.31e-05	0.00497	CbGpPWpGaD
Felbamate—GRIN2B—Transmission across Chemical Synapses—BRAF—bone cancer	9.21e-05	0.00492	CbGpPWpGaD
Felbamate—GRIN2A—Transmission across Chemical Synapses—MDM2—bone cancer	9.07e-05	0.00485	CbGpPWpGaD
Felbamate—GRIN2B—BDNF signaling pathway—JUN—bone cancer	8.72e-05	0.00466	CbGpPWpGaD
Felbamate—GRIN2A—Neuronal System—BRAF—bone cancer	8.3e-05	0.00443	CbGpPWpGaD
Felbamate—GRIN2B—Transmission across Chemical Synapses—MDM2—bone cancer	7.72e-05	0.00412	CbGpPWpGaD
Felbamate—CYP2E1—Biological oxidations—CYP3A4—bone cancer	7.33e-05	0.00391	CbGpPWpGaD
Felbamate—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	7.23e-05	0.00386	CbGpPWpGaD
Felbamate—GRIN2B—Axon guidance—MET—bone cancer	7.08e-05	0.00378	CbGpPWpGaD
Felbamate—GRIN2B—Neuronal System—BRAF—bone cancer	7.06e-05	0.00377	CbGpPWpGaD
Felbamate—GRIN2A—Neuronal System—MDM2—bone cancer	6.95e-05	0.00371	CbGpPWpGaD
Felbamate—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	6.73e-05	0.00359	CbGpPWpGaD
Felbamate—CYP2E1—Biological oxidations—GSTP1—bone cancer	6.27e-05	0.00335	CbGpPWpGaD
Felbamate—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	6.18e-05	0.0033	CbGpPWpGaD
Felbamate—GRIN2B—Neuronal System—MDM2—bone cancer	5.91e-05	0.00316	CbGpPWpGaD
Felbamate—GRIN2B—Axon guidance—MMP2—bone cancer	5.9e-05	0.00315	CbGpPWpGaD
Felbamate—CYP2C19—Biological oxidations—CYP3A4—bone cancer	5.65e-05	0.00302	CbGpPWpGaD
Felbamate—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	5.58e-05	0.00298	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—MET—bone cancer	5.05e-05	0.0027	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—CDK4—bone cancer	5.05e-05	0.0027	CbGpPWpGaD
Felbamate—CYP2C19—Biological oxidations—GSTP1—bone cancer	4.84e-05	0.00258	CbGpPWpGaD
Felbamate—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	4.77e-05	0.00255	CbGpPWpGaD
Felbamate—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.49e-05	0.0024	CbGpPWpGaD
Felbamate—GRIN2B—Axon guidance—MMP9—bone cancer	4.44e-05	0.00237	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—NDUFA12—bone cancer	4.39e-05	0.00235	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—MMP2—bone cancer	4.21e-05	0.00225	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—NT5C3A—bone cancer	3.64e-05	0.00194	CbGpPWpGaD
Felbamate—GRIN2B—Axon guidance—EGFR—bone cancer	3.58e-05	0.00191	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—NDUFA12—bone cancer	3.39e-05	0.00181	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—MMP9—bone cancer	3.17e-05	0.00169	CbGpPWpGaD
Felbamate—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.91e-05	0.00155	CbGpPWpGaD
Felbamate—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.87e-05	0.00153	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—NT5C3A—bone cancer	2.81e-05	0.0015	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—EGFR—bone cancer	2.56e-05	0.00137	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—NDUFA12—bone cancer	2.04e-05	0.00109	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—NT5C3A—bone cancer	1.69e-05	0.000902	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—ENO2—bone cancer	1.59e-05	0.000851	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—DHFR—bone cancer	1.48e-05	0.00079	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—GNA11—bone cancer	1.38e-05	0.000738	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—CYP3A4—bone cancer	1.25e-05	0.000669	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—ENO2—bone cancer	1.23e-05	0.000657	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—DHFR—bone cancer	1.14e-05	0.000609	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—GSTP1—bone cancer	1.07e-05	0.000572	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—GNA11—bone cancer	1.07e-05	0.000569	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—CYP3A4—bone cancer	9.67e-06	0.000516	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.62e-06	0.000514	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—GSTP1—bone cancer	8.27e-06	0.000442	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—ENO2—bone cancer	7.4e-06	0.000395	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—DHFR—bone cancer	6.86e-06	0.000366	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—GNA11—bone cancer	6.41e-06	0.000342	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—PTGS2—bone cancer	5.55e-06	0.000296	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—GSTP1—bone cancer	4.97e-06	0.000266	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—PTGS2—bone cancer	4.28e-06	0.000229	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—PTGS2—bone cancer	2.58e-06	0.000138	CbGpPWpGaD
